Flow Cytometry Instruments and Reagents

The company was founded in 1897 in New York City by Maxwell Becton and Fairleigh S. Dickinson. We know that possibilities are endless when people feel supported and inspired. At BD, we believe that people are at the heart of every breakthrough, solution, and step forward.

BD can help you identify potential “at-risk” patients, empower clinical intervention, and advance health system insights A unique ecosystem to collaborate on flow cytometry panel design, improve cytometer efficiency and manage https://chickenroadonline-bd.com/ your laboratory. An interactive tool containing key cell information to help plan your flow cytometry experiments. The BD Rhapsody™ single-cell platform has been a key tool for the publication of our clinical research. Food and Drug Administration and worldwide health agencies to coordinate recall activities.

• They found repeat and serious violations of health and safety law that had resulted in two employees having partial finger amputations.
• BD recalled and tested the syringes in question, and revealed sterile particulates in 0.013 percent of the products.
• BD announced that it notified customers about the recall by letter and has been working with the U.S.

Quality Engineer jobs

Explore a variety of tools for your multicolor flow cytometry, from panel design to selection tools—an array of aids to support your research. These subtle changes would not have been discovered without the use of a powerful, highly sensitive technique such as the BD Rhapsody™ single-cell platform. It allowed us to study gene expression from immune populations of frozen PBMCs from people living with HIV after a nutritional intervention. Fill out the form to receive updates on our latest products and innovations, exclusive promotions, educational tours, and other exciting news. Backed by cutting-edge technology and more than 50 years of flow cytometry expertise

Innovative solutions to power your diagnostics and research

This agreement protects patents and intellectual properties of both companies ensuring the quality and integrity of Embecta Corporation’s cannulas used in their products. The transaction was completed later that year, and the company became a wholly-owned subsidiary of BD, rebranded as Bard. In October 2014, the company agreed to acquire CareFusion for a price of US$12.2 billion in cash and stock. Later Retractable would claim BD was falsely advertising its own brand of retractable needle as the “world’s sharpest needle”. Retractable would accuse BD of patent infringement after BD released a retractable needle of its own. The lawsuit touched off a series of legal conflicts between the companies.

Medical Equipment Manufacturing

The approximately 2.8 million BD Q-Syte and 2.9 million BD Nexiva units containing 5 million BD Q-Syte devices that were recalled were distributed in the United States, Asia, Canada, Europe, Mexico, the Middle East, South Africa, and South America. BD recalled and tested the syringes in question, and revealed sterile particulates in 0.013 percent of the products. They found repeat and serious violations of health and safety law that had resulted in two employees having partial finger amputations. Embecta Corporation is a standalone public company focused on diabetes care.

Designed and validated for use with cell suspensions, whole blood and tissue pieces. BD Horizon RealViolet™ 544 Reagents offer limited spillover, robust intracellular performance and lot-to-lot consistency. In December 2025, BD was sued by Tela Bio Inc., makers of a ovine forestomach matrix hernia mesh, who alleged that BD engaged in anticompetitive practices to push Tela out of the market for surgical meshes while raising prices for providers and patients.